Perceptive Advisors
Perceptive Advisors is a privately owned hedge fund sponsor that finances the public equity markets across the globe.
Business Model:
Revenue: $13.7M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Perceptive Advisors Information
Geographic Data
Address: 499 Park Ave
City: New York
State: NY
Zip: 10022
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$2B
Social
Linkedin
Crunchbase
Metrics
2,160,524Website Global Rank
9,065Website Monthly Traffic
Twitter Followers
Description
Perceptive Advisors, LLC is a privately owned hedge fund sponsor. The firm invests in the public equity markets across the globe. It employs a long/short equity strategy as a hedging technique while making its investments. The firm typically invests in biotechnology and life sciences sectors to make its investments. Perceptive Advisors is based in New York, New York.
Contact Phone:
+16462055340
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 5/2017 | Home Dialysis Plus | Series C | 76.5M |
| 9/2020 | Willow | Series C | 0 |
| 6/2020 | C4 Therapeutics | Series B | 150M |
| 7/2019 | Frequency Therapeutics | Series C | 0 |
| 4/2021 | Forge Biologics | Series B | 120M |
| 5/2016 | AVEO Oncology | Post-IPO Equity | 17M |
| 10/2021 | Honor | Debt Financing | 300M |
| 9/2018 | Lyra Therapeutics | Series B | 0 |
| 7/2018 | Alector | Series E | 133M |
| 1/2016 | Arno Therapeutics | Post-IPO Equity | 0 |
| 12/2015 | Clearside Biomedical | Series C | 20M |
| 9/2021 | Hancock Jaffe Laboratories | Post-IPO Equity | 20M |
| 3/2018 | IDEAYA Biosciences | Series B | 0 |
| 8/2016 | Arno Therapeutics | Post-IPO Equity | 8M |
| 10/2021 | Science 37 | Post-IPO Equity | 0 |
| 3/2015 | Minerva Neuroscience | Post-IPO Equity | 0 |
| 7/2014 | Virobay | Series B | 8M |
| 12/2019 | Quellis Biosciences | Series A | 0 |
| 6/2020 | 4D Molecular Therapeutics | Series C | 0 |
| 9/2021 | A-Alpha Bio | Series A | 20M |
| 10/2022 | immatics biotechnologies | Post-IPO Equity | 0 |
| 3/2020 | immatics biotechnologies | Post-IPO Equity | 0 |
| 1/2022 | Orchestra BioMed | Series D | 0 |
| 3/2015 | Champions Oncology | Post-IPO Equity | 14M |
| 1/2022 | AvengeBio | Series A | 0 |
| 6/2019 | PanTheryx | Venture Round | 50M |
| 2/2020 | Agile Therapeutics | Post-IPO Debt | 20M |
| 12/2019 | Zentalis Pharmaceuticals | Series C | 85M |
| 9/2017 | BridgeBio Pharma | Series C | 135M |
| 5/2017 | Xontogeny | Series A | 15M |
| 7/2019 | Neptune Wellness Solutions | Post-IPO Equity | 41.4M |
| 5/2019 | ArcherDX | Series B | 60M |
| 11/2015 | Solid Biosciences | Series B | 42.5M |
| 11/2020 | Prometheus Biosciences | Equity | 130M |
| 12/2021 | Mythic Therapeutics | Series B | 0 |
| 9/2018 | Vapotherm | Series D | 0 |
| 4/2020 | Dynacure | Series C | 54.2M |
| 9/2020 | Zymergen | Series D | 300M |
| 12/2019 | ArcherDX | Series C | 0 |
| 5/2018 | MEI Pharma | Post-IPO Equity | 75M |
| 6/2021 | PROCEPT BioRobotics | Series G | 0 |
| 2/2018 | PROCEPT BioRobotics | Series E | 0 |
| 7/2015 | GenSight Biologics | Series B | 0 |
| 1/2021 | Earli | Series A | 40M |
| 10/2021 | Twin Health | Series C | 155M |
| 1/2021 | Impulse Dynamics | Series D | 60M |
| 4/2019 | Fusion Pharmaceuticals | Series B | 0 |
| 3/2019 | Saama | Venture Round | 40M |
| 5/2017 | Outset Medical | Series C | 0 |
| 6/2020 | DNAnexus | Series G | 0 |
| 6/2020 | Fulcrum Therapeutics | Post-IPO Equity | 0 |
| 5/2020 | Nautilus Biotechnology | Series B | 76M |
| 3/2021 | Pyxis Oncology | Series B | 152M |
| 11/2017 | Counsyl | Equity | 80M |
| 5/2021 | Cue | Venture Round | 235M |
| 6/2016 | VitalConnect | Series B | 18M |
| 7/2018 | Athenex | Post-IPO Equity | 50M |
| 9/2020 | I-Mab Biopharma | Post-IPO Equity | 0 |
| 4/2019 | Kindbody | Series A | 15M |
| 3/2018 | Crinetics Pharmaceuticals | Series B | 63.5M |
| 10/2020 | LianBio | Series A | 0 |
| 1/2020 | Sonendo | Venture Round | 85M |
| 7/2021 | Sema4 | Post-IPO Equity | 350M |
| 12/2019 | Black Diamond Therapeutics | Series C | 0 |
| 7/2020 | Cerevel Therapeutics | Post-IPO Equity | 0 |
| 12/2016 | VBI Vaccines | Post-IPO Equity | 10.6M |
| 12/2016 | VBI Vaccines | Post-IPO Debt | 13M |
| 1/2021 | Clover Health | Post-IPO Equity | 400M |
| 3/2023 | CARGO Therapeutics | Series A | 0 |
| 1/2019 | Black Diamond Therapeutics | Series B | 85M |
| 4/2017 | Singulex | Debt Financing | 50M |
| 1/2018 | AEGEA Medical | Series D | 0 |
| 6/2020 | C4 Therapeutics | Debt Financing | 20M |
| 5/2018 | Rain Therapeutics | Series A | 18.4M |
| 11/2015 | Celladon | Post-IPO Equity | 39.5M |
| 5/2021 | NiKang Therapeutics | Series C | 200M |
| 8/2019 | Landos Biopharma | Series B | 60M |
| 9/2022 | InSightec | Debt Financing | 100M |
| 8/2020 | Freenome | Series C | 270M |
| 2/2019 | ADMA Biologics | Post-IPO Debt | 72.5M |
| 8/2016 | Vyome Therapeutics | Series C | 14M |
| 8/2021 | Bridge to Life | Venture Round | 56M |
| 7/2020 | Frequency Therapeutics | Post-IPO Equity | 42.3M |
| 8/2018 | Outset Medical | Series D | 0 |
| 1/2020 | Cerebral Therapeutics | Series B | 35M |
| 9/2020 | Rain Therapeutics | Series B | 63M |
| 10/2013 | Arno Therapeutics | Post-IPO Equity | 0 |
| 9/2017 | Landos Biopharma | Series A | 10M |
| 1/2018 | Vitruvias Therapeutics | Series A | 11.5M |
| 5/2020 | Omada Health | Venture Round | 57M |
| 9/2022 | SpringWorks Therapeutics | Post-IPO Equity | 225M |
| 10/2014 | Zynerba Pharmaceuticals | Venture Round | 13M |
| 3/2021 | Scribe Therapeutics | Series B | 100M |
| 7/2020 | Pear Therapeutics | Debt Financing | 50M |
| 6/2015 | Outset Medical | Debt Financing | 45M |
| 12/2021 | Freenome | Series D | 300M |
| 8/2018 | ReViral | Series B | 0 |
| 11/2021 | Sermonix | Series A | 40M |
| 7/2016 | VBI Vaccines | Post-IPO Equity | 0 |
| 4/2018 | Kodiak Sciences | Convertible Note | 33M |
| 5/2019 | Athenex | Post-IPO Equity | 100M |
| 9/2016 | Establishment Labs | Debt Financing | 15M |
| 6/2020 | AsclepiX Therapeutics | Series A | 35M |
| 1/2022 | Ceptur Therapeutics | Series A | 0 |
| 9/2015 | Outlook Therapeutics | Venture Round | - |
| 1/2021 | Affinivax | Series C | 226M |
| 3/2022 | VivoSense | Series A | 0 |
| 7/2019 | Foamix | Post-IPO Debt | 64M |
| 11/2022 | Biodesix | Post-IPO Debt | 50M |
| 7/2020 | Verona Pharma | Private Placement | 200M |
| 12/2016 | Motus GI | Venture Round | 0 |
| 7/2020 | Thrive Earlier Detection | Series B | 0 |
| 8/2017 | Molecular Templates | Post-IPO Equity | 60M |
| 1/2021 | DarioHealth | Post-IPO Equity | 70M |
| 7/2019 | Kronos Bio | Series A | 105M |
| 4/2019 | Poseida Therapeutics | Series C | 0 |
| 4/2022 | Lyra Therapeutics | Post-IPO Equity | 0 |
| 12/2016 | Vensun Pharmaceuticals | Series C | 22.5M |
| 12/2020 | Neuron23 | Series B | 80M |
| 9/2018 | 4D Molecular Therapeutics | Series B | 0 |
| 7/2020 | Kindbody | Series B | 0 |
| 2/2021 | Day One Biopharmaceuticals | Series B | 130M |
| 8/2014 | Bellicum Pharmaceuticals | Series C | 55M |
| 10/2020 | AavantiBio | Series A | 0 |
| 1/2020 | Lyra Therapeutics | Series C | 0 |
| 5/2020 | Atea | Series D | 215M |
| 8/2021 | Zentera Therapeutics | Series B | 75M |
| 5/2007 | Spectrum Pharmaceuticals | Post-IPO Equity | 0 |
| 2/2021 | Nuvation Bio | Post-IPO Equity | 502M |
| 7/2020 | Forge Biologics | Series A | 40M |
| 5/2021 | Juno Diagnostics | Series A | 25M |
| 2/2022 | Synthego | Series E | 0 |
| 3/2019 | Orchestra BioMed | Series B | 34M |
| 12/2022 | Apogee Therapeutics | Series B | 0 |
| 10/2016 | True North Therapeutics | Series D | 45M |
| 7/2019 | Beta Bionics | Series B | 63M |
| 1/2019 | BridgeBio Pharma | Equity | 299.2M |
| 3/2022 | DNAnexus | Series H | 200M |
| 10/2014 | Invitae | Series F | 0 |
| 11/2015 | Vapotherm | Series C | 0 |
| 4/2019 | SpringWorks Therapeutics | Series B | 125M |
| 4/2014 | Otonomy | Series D | 49M |
| 2/2022 | Endeavor BioMedicines | Series B | 101M |
| 7/2019 | Freenome | Series B | 160M |
| 8/2020 | Kronos Bio | Private Equity Round | 155M |
| 9/2020 | Escient Pharmaceuticals | Series B | 77.5M |
| 5/2023 | OnKure Therapeutics | Series C | 0 |
| 11/2020 | Achilles Therapeutics | Series C | 69.8M |
| 7/2021 | Point Biopharma | Post-IPO Equity | 0 |
| 8/2020 | Taysha Gene Therapies | Series B | 0 |
| 9/2022 | Solid Biosciences | Post-IPO Equity | 75M |
| 4/2021 | Icosavax | Series B | 0 |
| 11/2021 | Acrivon Therapeutics | Series B | 0 |
| 3/2017 | Solid Biosciences | Series C | 0 |
| 6/2021 | Nautilus Biotechnology | Post-IPO Equity | 0 |
| 8/2021 | Genome Medical | Series C | 0 |
| 6/2019 | Genome Medical | Series B | 23M |
| 5/2021 | Affinia Therapeutics | Series B | 0 |
| 3/2022 | Neuron23 | Series C | 0 |
| 2/2021 | Pipeline Therapeutics | Series C | 0 |
| 11/2022 | Zenas BioPharma | Series B | 0 |
| 6/2020 | Athira Pharma | Series B | 85M |
| 5/2023 | Lyra Therapeutics | Post-IPO Equity | 0 |
| 9/2019 | Achilles Therapeutics | Series B | 120.9M |
| 6/2021 | Kindbody | Series C | 0 |
| 5/2019 | Confo Therapeutics | Series A | 33.6M |
| 12/2015 | True North Therapeutics | Series C | 40M |
| 1/2021 | Beam Therapeutics | Post-IPO Equity | 260M |
| 3/2021 | OnKure | Series B | 56.6M |
| 8/2018 | Orchard Therapeutics | Series C | 0 |
| 1/2021 | MIVI Neuroscience | Series B | 35M |
| 3/2021 | Crossover Health | Series D | 0 |
| 9/2021 | HilleVax | Equity | 135M |
| 8/2019 | Oncorus | Series B | 0 |
| 6/2015 | CytomX Therapeutics | Series D | 70M |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 6/2021 | RayzeBio | Series C | 108M |
| 12/2021 | Hyperfine | Post-IPO Equity | 0 |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 7/2021 | Amylyx Pharmaceuticals | Series C | 0 |
| 11/2014 | Blueprint Medicines | Series C | 50M |
| 1/2016 | Zymeworks | Series A | 0 |
| 5/2017 | Vapotherm | Series D | 0 |
| 12/2018 | Relay Therapeutics | Series C | 0 |
| 9/2018 | Allogene | Convertible Note | 0 |
| 11/2019 | Avidity Biosciences | Series C | 0 |
| 4/2021 | Renovia | Series C | 0 |
| 6/2020 | CereVasc | Series A | 44M |
| 8/2020 | Metabolon | Venture Round | 72M |
| 8/2022 | MeiraGTx | Post-IPO Debt | 75M |
| 3/2010 | Sevion Therapeutics | Post-IPO Equity | 0 |
| 1/2021 | IsoPlexis | Series D | 85M |
| 1/2021 | IsoPlexis | Debt Financing | 50M |
| 6/2016 | Corbus Pharmaceuticals | Post-IPO Equity | 14.8M |
| 11/2018 | Medicrea | Post-IPO Debt | 30M |
| 3/2020 | Zucara Therapeutics | Series A | 21M |
| 7/2019 | AgaMatrix | Debt Financing | 56M |
| 3/2021 | Absci | Venture Round | 0 |
| 5/2015 | REGENXBIO | Series D | 0 |
| 3/2018 | Molecular Templates | Post-IPO Debt | 10M |
| 8/2016 | Aquestive Therapeutics | Debt Financing | 50M |
| 8/2018 | Renovia | Series B | 32.3M |
| 5/2017 | Synlogic | Series C | 42M |
| 8/2017 | Dova Pharmaceuticals | Post-IPO Equity | - |
| 12/2020 | Solid Biosciences | Post-IPO Equity | 0 |
| 7/2020 | Cogent Biosciences | Post-IPO Equity | 104.4M |
| 8/2020 | ReViral | Series C | 0 |
| 1/2019 | Vyome Therapeutics | Series D | 22M |
| 7/2020 | Genome Medical | Series B | 0 |
| 2/2018 | Partner Therapeutics | Series A | 60M |
| 4/2022 | Surf Bio | Seed | 16M |
| 11/2020 | Adagio Medical | Series E | 0 |
| 7/2015 | Outlook Therapeutics | Venture Round | 31M |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 4/2018 | Eidos Therapeutics | Series B | 0 |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 12/2005 | EUSA Pharma | Venture Round | 0 |
| 9/2021 | Emulate | Series E | 82M |
| 4/2020 | COMPASS Pathways | Series B | 0 |
| 9/2021 | SomaLogic | Post-IPO Equity | 0 |
| 2/2022 | Beta Bionics | Series C | 0 |
| 6/2022 | Cerebral Therapeutics | Series C | 40M |
| 6/2015 | Alliqua BioMedical | Post-IPO Debt | 15.5M |
| 7/2016 | Ardelyx | Post-IPO Equity | 0 |
| 9/2014 | Affimed | Debt Financing | 14M |
| 2/2022 | Omada Health | Series E | 0 |
| 8/2022 | MeiraGTx | Post-IPO Debt | 0 |
| 6/2022 | Cerebral Therapeutics | Series C | 0 |
| 4/2022 | Surf Bio | Seed Round | 0 |
| 4/2022 | Lyra Therapeutics | Post-IPO Equity | 0 |
| 3/2022 | VivoSense | Series A | 0 |
| 3/2022 | Neuron23 | Series C | 0 |
| 3/2022 | DNAnexus | Series H | 0 |
| 2/2022 | Omada Health | Series E | 0 |
| 2/2022 | Synthego | Series E | 0 |
| 2/2022 | Beta Bionics | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
